(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree- Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
- Astronaut on ISS captures spectacular orbital video of zodiacal light, auroras and the Pleiades
- Fundamental Monetary Guidance for Going into Business
- Deaths reported in Lebanon as Israel and Hezbollah exchange attacks
- NMG signs new graphite supply deal with Canadian Government
- Factbox-China's crewed lunar programme eyes astronaut landing by 2030
- The German series proving subtitles can be sexy — and wildly addictive
- Daily Briefing: A bad flu season gets worse
